Dividend Growth Portfolio Holding Phillips 66 Caps Off 2012 with an Outstanding Fourth Quarter
January 30, 2013
Dividend Growth Newsletter portfolio holding Phillips 66 (click ticker for report: ) announced another fantastic quarter Wednesday morning. The company has been one of the biggest winners in the portfolio of our Dividend Growth Newsletter. We expect to update our dividend report on the firm soon. Adjusted earnings per share jumped over 240% year-over-year to $2.06, smashing consensus estimates. Earnings for the year jumped 50% to $8.46, highlighting the considerable operating leverage inherent to the refinery business. Shares are now up over 90% since being spun off from ConocoPhillips (click ticker for report: ) in 2012. Cash flow generation was superb, as the firm raked in $1.3 billion in operating cash flow. $1 billion was used to reduce debt, leaving the
Amazon Reports Strong Sales Growth
January 30, 2013
Online retail kingpin Amazon (click ticker for report: ) reported strong sales growth during its fourth quarter. Revenue jumped 22% year-over-year to $21.3 billion, slightly below expectations, but still strong. Earnings, as is the norm for Amazon, missed the mark, falling nearly 50% year-over-year to $0.21 per share. Although classic value investors and growth investors alike remain baffled by Amazon’s current price-to-earnings multiple (the firm posted a net loss for 2012), we do not think multiple analysis really tells the story at Amazon. Nor does near-term free cash flow, which was 81% lower on 7% higher operating cash flow during the period. Amazon is investing for the future, and given its current sales pace, we think the market is pricing in a dramatic rise in
Pfizer and Eli Lilly Report Strong Performance; Drug Pipelines Continue to Advance
January 30, 2013
Pfizer (click ticker for report: ) and Eli Lilly (click ticker for report: ) reported their respective fourth-quarter results Tuesday, and we were pleased with the performance. Pfizer’s $15.1 billion in revenue (down 7%) and $0.47 in adjusted earnings per share (down 4%) topped estimates, while Eli Lilly’s $5.96 billion in revenue (down 1%) and $0.85 in earnings per share (down 2%) also surprised the Street to the upside. Both companies are dealing with patent expiration on blockbuster drugs—Pfizer’s cholesterol-fighter Lipitor and Lilly’s schizophrenia drug Zyprexa. Pfizer expects to stem the losses from Lipitor with new drugs such as Xeljanz for rheumatoid arthritis and Eliquis, an anti-clotting drug that helps prevent stroke and systemic embolism in patients with nonvalvular atrial
Ford Posts a Fantastic Fourth Quarter
January 29, 2013
Earlier this morning, Best Ideas Newsletter portfolio holding Ford (click ticker for report: ) reported fantastic fourth-quarter results that capped off one of the company’s strongest years in its long history. Revenue increased 5% year-over-year to $36.5 billion, easily exceeding consensus estimates. Pre-tax operating profit more than doubled to $1.2 billion, which was also better than anticipated. We see no reason to change our above-market fair value estimate, and we remain very bullish on the company (Image Source: F Earnings Presentation). Not surprisingly, North America (shown above) continued to be the standout segment, with revenue increasing nearly 13% year-over-year and the firm’s operating margin advancing 390 basis points higher. There is some concern about the company losing US market share
JC Penney Brings Back Discounting; Was the Fourth Quarter Horrible?
January 29, 2013
Last week, rumors swirled that JC Penney (click ticker for report: ) was pressuring its suppliers to place MSRPs (manufacturer’s suggested retail price) on its products so JCP could appear to be giving consumers a discount on a product (a sale without it actually being on-sale). Earlier today, that move was confirmed, and sales and MSRPs will be reintroduced at Penney’s stores around the country. Much-maligned CEO Ron Johnson noted that the strategy shift was an “evolution” rather than an admittance of failure. Yet, the idea of including MSRPs or comparable prices isn’t at all a unique idea—just look at any TJX (click ticker for report: ) store, Nordstrom Rack (click ticker for report: ), or Ross (click ticker for
Record Performance in 2012 at Caterpillar
January 29, 2013
Let’s dig into Caterpillar’s fourth-quarter results and economic outlook for 2013.
Marissa Mayer’s Yahoo! Revitalization Continues
January 29, 2013
Monday afternoon, former tech darling Yahoo! (click ticker for report: ) reported solid fourth-quarter results. Revenue jumped 2% year-over-year to $1.35 billion, and revenue ex-TAC (traffic acquisition costs) came in at $1.2 billion, a 4% year-over-year increase that was in line with consensus expectations. Operating earnings per share jumped 28% year-over-year to $0.32, easily exceeding consensus estimates. As wonderful as it is to see revenue grow, the real story at Yahoo! remains the turnaround that CEO Marissa Mayer has embarked upon. Given the incredibly competitive market for talent in the tech industry, Mayer has worked to transform the company into one of Silicon Valley’s best places to work. She noted in the conference call: To date, we introduced rigorous hiring
Coach’s Momentum Is Slowing
January 29, 2013
Aspirational luxury brand Coach (click ticker for report: ) announced lackluster results for its fiscal year 2013 second quarter and the holiday season. Revenue increased just 4% year-over-year to $1.5 billion, short of consensus expectations. Earnings missed the mark by several cents, growing just 4% year-over-year to $1.23 per share. Our fair value estimate remains unchanged. Gross margins remained basically unchanged year-over-year at 72.1%, suggesting the company did not take markdowns during the quarter. Unfortunately, the firm’s 4% sales expansion trailed the 15% increase in inventories, which could indicate that markdowns may come eventually. We could see a gross margin figure meaningfully lower than the current low-70’s run-rate in the coming periods. Inventory growth was among the primary reasons why
The Significance of Changes in Our Valuentum Buying Index (VBI) Ratings
January 29, 2013
Astronics (ATRO) has been a darling of a stock for our Best Ideas portfolio, despite hitting a very rough patch recently. Our Valuentum Buying Index (VBI) ratings have helped us maximize profits in the company, informing us to add the firm in June 2011 to our Best Ideas portfolio in the low-mid $20s (VBI rating of 10) and then to potentially take some profits when the firm registered a VBI rating of 6 in late 2011/early 2012 in the mid-$30s, which we did (selling 30% and then another 50% of our position). We view VBI ratings of 9 and 10 as actionable for us on the long side and VBI ratings of 1 or 2 as actionable for us on the short (put-option) side. However, we
Jos. A. Bank’s Friday Night Update Reveals Huge Profit Shortfall
January 29, 2013
Late Friday night, suit retailer Jos. A. Bank (click ticker for report: ) used a common tactic to report bad news, revealing in an 8-K that net income for 2012 will be approximately 20% lower than it was in 2011. Some simple mathematical calculations reveal that the figure will lead to lower EPS in not only 2011, but also below what the firm reported in 2010. Although we’re sure SG&A has increased as a percentage of sales, we think the terrible results are the product of compressing gross margins. The firm is famous for its “Buy 1, Get 2 Free” marketing, though it sometimes extends to buying one suit for a free shirt, tie, socks, and other accessories. While Jos.
